IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Fax: +358 9 8520 2034
Email: firstname.lastname@hexal.fi
Home Page: www.hexal.fi
De scrip tion: Pro moter. Prod uct ranges in clude:
phar ma ceu ti cal prod ucts (branded, unbranded,
pre scrip tion, non-pre scrip tion), hos pi tal
pharmaceuticals. Es tab lished 1990. 17 phar ma -
ceu ti cal employees in 2005.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 7 (2005)
Con tacts (Pharm): Chair man: Timo Nurmi;
Com mer cial Op er a tions: Marko Sandberg; Gen -
eral Con tact: Mari Wuori
Phar ma ceu ti cal Sales: US$ 16-18 mil lion
Prod ucts (% of Sales by Lead ing 5): 55-60%
Ther a peu tic Classes (% of Sales by Lead ing
5): 70-75%
Dose Forms (% of Sales by Lead ing 5):
95-100%
Prin ci pal Prod ucts:
LINATIL COMP (ACE in hib i tor com bi na tion)
LIPCUT (cho les terol/triglyceride reg u lat ing prep a -
ra tion)
GEFINA (BPH (be nign pros tatic hy per tro phy)
prod uct)
METOHEXAL (beta-blocker agent plain)
LINATIL (ACE in hib i tor plain)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 26%
lipid-reg u lat ing/antiatheroma prep a ra tions
14%
beta-block ing agents 12%
urologicals 11%
antigout prep a ra tions 8%
Lead ing Dose Forms:
tab lets 53%
coated tab lets 38%
cap sules 4%
med i cal dress ings 2%
creams 2%
NOVARTIS
Full Name: Novartis Fin land Oy
Street Ad dress: Metsaenneidonkuja 10,
FIN-02130 Espoo
Tel: +358 96 133 2211
Fax: +358 98 550 0003
Home Page: www.novartis.fi
De scrip tion: Re searcher, im porter, pro moter.
Prod uct ranges in clude: phar ma ceu ti cal prod ucts
(branded, pre scrip tion, non-pre scrip tion), hos pi -
tal pharmaceuticals, oph thal mic prod ucts, vet er i -
nary pharmaceuticals. Es tab lished 1997. 125
phar ma ceu ti cal em ploy ees in 2008. Di vi sions in -
clude: Pharmaceuticals; Consumer Health
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 51-100 (2008)
Con tacts (Pharm): Chair man: Antti Viitanen;
Com mer cial Op er a tions: Merja
Lankinen-Liflander, Alexis Burekhardt; Mar ket
Re search: Jaana-Liisa Aro; Re search & De vel op -
ment: Maarit Hillila; Gen eral Con tact: Jaana-Liisa
Aro
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 110-120 mil lion
Prod ucts (% of Sales by Lead ing 5): 50-55%
Ther a peu tic Classes (% of Sales by Lead ing
5): 55-60%
Dose Forms (% of Sales by Lead ing 5):
85-90%
Prin ci pal Prod ucts:
EXELON (anti-Alz hei mer prod uct)
GLIVEC (antineoplastic other)
SANDIMMUN (immunosuppressive agent)
DIOVAN (an gio ten sin-II an tag o nist plain)
DIOVAN COMP (an gio ten sin-II an tag o nist com bi -
na tion)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 17%
CNS drugs other 14%
antineoplastics 12%
immunosuppressive agents 10%
hor mones pi tu itary and hy po tha lamic 7%
Lead ing Dose Forms:
coated tab lets 38%
cap sules 22%
tab lets 13%
am poules 7%
liq uids 7%
NOVARTIS CON SUMER HEALTH
Full Name: Novartis Fin land Oy
Street Ad dress: Metsanneidonkuja 10,
FIN-02130 Espoo
Tel: +358 9 6133 2211
Fax: +358 9 6133 2200
Home Page: www.novartis.fi
De scrip tion: Im porter, pro moter, sales/detailer.
Prod uct ranges in clude: phar ma ceu ti cal prod ucts
(branded, unbranded, pre scrip tion, non-pre scrip -
tion), hos pi tal pharmaceuticals, vet er i nary
pharmaceuticals, oph thal mic prod ucts. Es tab -
lished 1996. 200 phar ma ceu ti cal em ploy ees in
© 2009 IMS Health In cor po rated or its af fil i ates Page 167